XERS - NASDAQ
Xeris Biopharma Holdings, Inc.
$6.13
+2.1%Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
At a Glance
Live SnapshotXeris Biopharma Holdings, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Cash Flow Quality Insight
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
Xeris Biopharma Holdings, Inc. Cash Flow Statement
XERS • NASDAQ
| Xeris Biopharma Holdings, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||
554K | -54.8M | -62.3M | -94.7M | -122.7M | -91.1M | -91.1M | -60.1M | -26.6M | -13.2M | |
12.2M | 12.6M | 13.2M | 12.7M | 1.9M | 1.5M | 1.5M | 320K | 177K | 116K | |
0.0 | -2.3M | -1.2M | -1.4M | -1.4M | 1.1M | 536K | -414K | 0.0 | 0.0 | |
22.4M | 18.4M | 10.7M | 12.2M | 11.4M | 8.3M | 6.5M | 1.7M | 499K | 540K | |
3.9M | -2M | -1.1M | 3.5M | 3.5M | 39K | 4.9M | 560K | 94K | 49K | |
-10.4M | -8.8M | -6.3M | -35.2M | 11.9M | -312K | -2.8M | 1.6M | 1.1M | -3.6M | |
28.6M | -37M | -47M | -102.9M | -95.5M | -80.6M | -80.6M | -56.3M | -24.7M | -16.1M | |
INVESTING ACTIVITIES | ||||||||||
-696K | -868K | -2.3M | -524K | -524K | -377K | -377K | -1.5M | -700K | -35K | |
(0.0) | (0.0) | (0.0) | (0.0) | (38.5M) | (0.0) | (377K) | (0.0) | (0.0) | (0.0) | |
(0.0) | -34.5M | -43.7M | (0.0) | -43M | -101.8M | -101.8M | -68.9M | (0.0) | (0.0) | |
0.0 | 40.2M | 40M | 35M | 35M | 74.7M | 74.7M | 2.1M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 4.6M | 0.0 | -377K | -66.8M | 0.0 | 0.0 | |
-696K | (4.9M) | -6M | (34.5M) | (34.5M) | -27.4M | -27.4M | -68.3M | -700K | -35K | |
FINANCING ACTIVITIES | ||||||||||
2.2M | -3.7M | -1M | 29.5M | 26.5M | 65.8M | 61.7M | 98.3M | 0.0 | 0.0 | |
9.2M | 38.2M | 0.0 | 102.7M | 0.0 | 69.8M | 25M | 35M | 0.0 | -32K | |
-10.9M | -3.7M | -1M | -468K | -534K | -63K | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 1.7M | -604K | -4.8M | 0.0 | -9.5M | 101.1M | -333K | -336K | -64K | |
11.4M | 36.2M | -1.6M | 127.5M | 27.2M | 126.1M | 126.1M | 128.2M | 35.1M | 3.9M | |
CASH FLOW SUMMARY | ||||||||||
0.0 | 0.0 | 0.0 | -4.3M | -3K | -3K | -22K | 0.0 | 0.0 | 0.0 | |
39.3M | 4.1M | -54.6M | 59M | 59M | 29.7M | 18.1M | 3.7M | 9.8M | -12.2M | |
75.7M | 71.7M | 126.3M | 67.3M | 67.3M | 37.6M | 19.5M | 42M | 32.3M | 44.5M | |
115.1M | 75.7M | 71.7M | 126.3M | 126.3M | 67.3M | 37.6M | 45.7M | 42M | 32.3M | |
27.9M | -37.8M | -49.3M | -103.4M | -103.4M | -96.6M | -80.9M | -57.8M | -25.4M | -16.1M |
SEC Filings
XERS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 21, 2026 | April 20, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 02, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 27, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 01, 2025 | December 01, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 |
Related Guides
Continue your XERS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.